(Reuters) – Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.
“Probably because of the number of opportunities, you will see us active in oncology – that’s where a lot of early stage biotech is,” Ricks said.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
